title: Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control.
abstract: BACKGROUND
  Although the mobilization of hematopoietic progenitor stem cells from healthy donors (HDs) using granulocyte-colony-stimulating factor is widely used, the ideal method for the administration of the cytokine has not yet been determined.
  
  
  METHODS
  Seventy-five consecutive HDs received lenograstim (LENO) as mobilization agent. LENO was given subcutaneously at a dose of 10 µg/kg in a once-daily dose (ODD) every 24 hours. Results were compared with a historical control group of 181 HDs treated with 5 µg/kg LENO twice-daily dose (TDD) with a time interval of 12 hours.
  
  
  RESULTS
  CD34+ cell concentrations evaluated on Day 4 and on Day 5 were 45 × 10(6) (range, 6 × 10(6) -217 × 10(6) )/L and 75 × 10(6) (range, 7 × 10(6) -279 × 10(6) )/L with ODD versus 36 × 10(6) (range, 3 × 10(6) -200 × 10(6) )/L and 55 × 10(6) (range, 3 × 10(6) -738 × 10(6) )/L with TDD (p = 0.067 and p = 0.001). The collected CD34+ cell counts in first apheresis procedure were 5.6 × 10(6)  ± 2.9 × 10(6) and 5.7 × 10(6)  ± 3 × 10(6) /kg donor and recipient body weight in the ODD versus 5.4 × 10(6)  ± 3.8 × 10(6) and 5.3 × 10(6)  ± 3.5 × 10(6) /kg in the TDD cohort, respectively (p = 0.08 and p = 0.02). Five HDs (6.7%) mobilized CD34+ cells of fewer than 2 × 10(6) /kg recipient body weight in the ODD group compared with seven HDs (3.9%) in the TDD group (p = 0.3).
  
  
  CONCLUSIONS
  Once-daily administration of LENO is at least as effective as twice-daily administration for the mobilization of CD34+ cells in HDs.
authors: Hematology and Stem Cells Transplantation Unit, CTMO, CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Massimo
authors: M
authors: Martino
authors: Hematology and Stem Cells Transplantation Unit, CTMO, CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Tiziana
authors: T
authors: Moscato
authors: Hematology and Stem Cells Transplantation Unit, CTMO, CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Santina
authors: S
authors: Barillà
authors: Hematology and Stem Cells Transplantation Unit, CTMO, CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Antonia
authors: A
authors: Dattola
authors: Hematology and Stem Cells Transplantation Unit, CTMO, CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Antonella
authors: A
authors: Pontari
authors: Hematology and Stem Cells Transplantation Unit, CTMO, CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Roberta
authors: R
authors: Fedele
authors: Immuno-Hematology and Transfusion Medicine, Azienda Ospedaliera "BMM", CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Giuseppe
authors: G
authors: Furlò
authors: Immuno-Hematology and Transfusion Medicine, Azienda Ospedaliera "BMM", CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Carmen
authors: C
authors: Marzia Stilo
authors: Hematology and Stem Cells Transplantation Unit, CTMO, CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Giuseppe
authors: G
authors: Alberto Gallo
authors: National Research Council (CRN), CRN Institute of Clinical Physiology, Reggio Calabria, Italy.
authors: Giovanni
authors: G
authors: Tripepi
mesh_terms: D000328:Adult; D064591:Allografts; D018952:Antigens, CD34 / Q000097:blood; D001781:Blood Component Removal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006402:Hematologic Diseases / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D065386:Historically Controlled Study; D006801:Humans; D007279:Injections, Subcutaneous; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000628:therapy; D010146:Pain / Q000139:chemically induced; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim